Xie Yi-Ting, Gao Jiang-Mei, Wu Ya-Ping, Tang Petrus, Hide Geoff, Lai De-Hua, Lun Zhao-Rong
Center for Parasitic Organisms, State Key Laboratory of Biocontrol, School of Life Sciences and Key Laboratory for Tropical Disease and Control of the Ministry of Education, Zhongshan College of Medicine, Sun Yat-Sen University, Guangzhou 510275, The People's Republic of China.
Bioinformatics Core Laboratory, Chang Gung University, Taoyuan, 333, Taiwan.
Parasit Vectors. 2017 Feb 16;10(1):83. doi: 10.1186/s13071-017-2009-8.
Human trichomoniasis caused by Trichomonas vaginalis is one of the most common sexually transmitted diseases with more than 200 million cases worldwide. It has caused a series of health problems to patients. For prevention and control of infectious diseases, vaccines are usually considered as one of the most cost-efficient tools. However, until now, work on the development of T. vaginalis vaccines is still mainly focused on the screening of potential immunogens. Alpha-actinin characterized by high immunogenicity in T. vaginalis was suggested as a promising candidate. Therefore, the purpose of this study was to evaluate the protective potency of recombinant α-actinin against T. vaginalis infection in a mouse intraperitoneal model.
Two selected coding regions of α-actinin (ACT-F, 14-469 aa and ACT-T, 462-844 aa) amplified from cDNA were cloned into pET-32a (+) expression vector and transfected into BL21 cells. After induction with IPTG and purification with electroelution, the two recombinant fusion proteins were emulsified in Freund's adjuvant (FA) and used to immunize BALB/C mice. Following intraperitoneal inoculation with T. vaginalis, the survival rate of mice was monitored for the assessment of protective potency. After immunization, the antibody level in mouse serum was assessed by ELISA, splenocyte proliferation response was detected with CCK8 and cytokines in the supernatant of splenocytes were quantified with a cytometric bead-based assay.
We successfully obtained purified ACT-F (70.33 kDa) and ACT-T (61.7kDa). Both recombinant proteins could provide significant protection against T. vaginalis challenge, especially ACT-T (with 100% protection within one month). Meanwhile, high levels of specific total IgG and subtypes (IgG1 > IgG2a) were detected in sera from the immunized mice. Our results also revealed a statistically significant increase in splenocyte proliferation and related cytokine (IFN-γ, IL-6, IL-17A and IL-10) production after repeated stimulation with the corresponding antigens in vitro.
Immunization with both ACT-F and ACT-T could confer partial to complete protection and trigger strong Th1/Th2 mixed humoral and cellular immune responses in the mouse host. This suggested that recombinant α-actinin subunit antigens may be promising vaccine candidates against trichomoniasis.
由阴道毛滴虫引起的人类滴虫病是最常见的性传播疾病之一,全球病例超过2亿例。它给患者带来了一系列健康问题。对于传染病的预防和控制,疫苗通常被认为是最具成本效益的工具之一。然而,到目前为止,阴道毛滴虫疫苗的研发工作仍主要集中在潜在免疫原的筛选上。在阴道毛滴虫中具有高免疫原性的α - 辅肌动蛋白被认为是一个有前景的候选者。因此,本研究的目的是在小鼠腹腔模型中评估重组α - 辅肌动蛋白对阴道毛滴虫感染的保护效力。
从cDNA中扩增出两个选定的α - 辅肌动蛋白编码区(ACT - F,14 - 469氨基酸和ACT - T,462 - 844氨基酸),克隆到pET - 32a(+)表达载体中并转染到BL21细胞中。用IPTG诱导并通过电洗脱纯化后,将这两种重组融合蛋白在弗氏佐剂(FA)中乳化,用于免疫BALB/C小鼠。在腹腔接种阴道毛滴虫后,监测小鼠的存活率以评估保护效力。免疫后,通过ELISA评估小鼠血清中的抗体水平,用CCK8检测脾细胞增殖反应,并用基于细胞计数微珠的测定法定量脾细胞上清液中的细胞因子。
我们成功获得了纯化的ACT - F(70.33 kDa)和ACT - T(61.7 kDa)。两种重组蛋白都能对阴道毛滴虫攻击提供显著保护,尤其是ACT - T(在一个月内保护率达100%)。同时,在免疫小鼠的血清中检测到高水平的特异性总IgG和亚型(IgG1 > IgG2a)。我们的结果还显示,在体外相应抗原反复刺激后,脾细胞增殖及相关细胞因子(IFN - γ、IL - 6、IL - 17A和IL - 10)产生有统计学显著增加。
用ACT - F和ACT - T免疫均可提供部分至完全保护,并在小鼠宿主中引发强烈的Th1/Th2混合体液和细胞免疫反应。这表明重组α - 辅肌动蛋白亚单位抗原可能是抗滴虫病的有前景的疫苗候选物。